Difference between revisions of "Anastrozole (Arimidex)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m (Text replacement - "Category:Drug index" to "Category:Drugs")
Line 24: Line 24:
 
<references/>
 
<references/>
  
[[Category:Drug index]]
+
[[Category:Drugs]]
 
[[Category:Oral medications]]
 
[[Category:Oral medications]]
 
[[Category:Protein expression-specific medications]]
 
[[Category:Protein expression-specific medications]]

Revision as of 23:04, 13 June 2018

General information

Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 12/27/1995: Initial FDA approval

Also known as

  • Brand names: Altraz, Anabrez, Anastraze, Anastrazol Rontag, Anastrol, Arimidex, Asiolex, Karomex, Leprofen, RUI SI YI, RUI Ting, Trozolet, Trozolite.

References